Blar i NTNU Open på forfatter "Sørensen, Boe Sandahl"
-
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Eide, Inger Johanne Zwicky; Stensgaard, Simone; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Sørensen, Boe Sandahl; Brustugun, Odd Terje (Peer reviewed; Journal article, 2022)Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 ...